Due Diligence and Art
Sasha LatypovaUncovering Fraud in Pharmaceutical R&D and Manufacturing. By popular demand, I will include my art pieces that have nothing to do with Pharma. If you are interested in my art, visit www.sashalatypova.com
| Platform |  | Pricing | Freemium | Publishes | Daily |
|---|---|---|---|---|---|
| Issues | 637 | Subscribers | Read | sashalatypova.substack.com |
Curious about how many subscribers Due Diligence and Art has or want to find similar newsletters? Reletter has got you covered. We collated all the information we could find from across the web in our database of over three million newsletters.
Check the email archives, get traffic estimates, engagement scores and more to discover the best advertising opportunities.
Our search tool helps you locate relevant newsletters for any topic and compare their stats for better sponsorship decisions.
Chart Rankings
How this newsletter ranks in the official Substack charts.
| #15 | |
| #17 |
Latest Issues
Recent posts by this newsletter. Browse the email archive.
Is Nattokinase a potential cure for the mRNA-induced fibrous clots?
You may have heard various statements from the alternative health space that nattokinase (NK), or “natto” is a potential cure for the micro clotting, thrombosis and formation of white fibrous clots that are found (typically post-mortem) in ...
Readers in Idaho: please call your representative and consider attending the March 25 hearing for S1346, a 2 year moratorium on mRNA "vaccines".
I am traveling to the Health Summit in Rochester, NY with organized by .
When the FDA biologics licensure (BLA) becomes a deadly joke: absurdities of Moderna's Spikevax nonclinical studies.
Big thanks to Cornelia for putting together these detailed discussions on the Moderna non-clinical “studies” on which the FDA issued [a very fake] Biologics License Approval for their Spikevax mRNA injections. This material is part of the ...
Similar Newsletters
Other publications recommended by the authors of this newsletter.
Authors
The writers behind this newsletter.
I could not become a professional artist, so I became a pharma and medical device R&D executive. If you are interested in my art, visit sashalatypova.com
Frequently Asked Questions
How can I access the email archive for Due Diligence and Art?
You can find recent issues that have been published by Due Diligence and Art on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does Due Diligence and Art have?
To see how many people subscribe to Due Diligence and Art, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in Due Diligence and Art?
Newsletter advertising can be extremely effective when it's done right. Before you pitch Due Diligence and Art as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like Due Diligence and Art?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact Due Diligence and Art using the contact information provided and ask for a copy of their media kit.
How can I find newsletters similar to Due Diligence and Art?
Scroll up to where it says Similar Newsletters to see other publications like Due Diligence and Art. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact Due Diligence and Art?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.